HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines
HLS Therapeutics has signed an agreement with Esperion Therapeutics for in-licensing and commercialising the oral cardiovascular medicines, Nexletol (bempedoic acid)…
